All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Not reported | 2004-001449-13 | Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy. | 2006-05-31 | due-trials |
Not reported | 2004-001450-84 | Safety and Efficacy of XM 02 in patients with small cell or non small cell lung cancer receiving platinum-based chemotherapy. Multinational, multicentre, randomised, controlled study | 2006-04-19 | due-trials |
Not reported | 2004-001452-36 | Efficacy and Safety of XM 02 compared to Filgrastim in patients with breast cancer receiving chemotherapy. Multinational, multicentre, randomised, controlled study | 2006-04-19 | due-trials |
Reported results | 2005-000140-85 | Efficacy and Safety of subcutaneous administration of XM01 and Epoetin beta for treatment of anaemia in chronic renal failure patients not yet receiving dialysis. A multinational, multicentre, randomi... | 2007-03-20 | due-trials |
Reported results | 2005-000142-37 | Efficacy and Safety of subcutaneous administration of XM01 compared to Epoetin beta in anaemic chronic renal failure patients not yet receiving dialysis and in maintenance phase treatment with Epoetin... | 2007-05-10 | due-trials |
Reported results | 2005-000144-87 | Long-term efficacy and safety of subcutaneous administration of XM01 in chronic renal failure patients and comparison of once-weekly with three-times weekly administration of XM01 - A multinational, m... | 2008-01-21 | due-trials |
Not reported | 2007-005349-39 | Dose-finding of a fixed dose XM22 in patients with breast cancer receiving 4 cycles of chemotherapy versus 6 mg Neulasta® | 2009-12-10 | due-trials |
Completed, but no date, and reported results | 2009-015999-10 | Efficacy and Safety of XM22 compared to pegfilgrastim in patients with breast cancer receiving chemotherapy. A multinational, multicentre, randomised, double-blind controlled study | bad-data | |
Reported results | 2009-016000-22 | Efficacy and safety of XM22 in patients with non small cell lung cancer receiving cisplatin / etoposide chemotherapy. A multinational, multicentre, randomised, double-blind placebo-controlled study | 2011-12-19 | due-trials |
Reported results | 2009-017674-20 | Efficacy, safety and tolerability of XM17 compared to Gonal-f® in women undergoing assisted reproductive technologies. A multi-national, multi-centre, randomised, controlled, assessor-blind, parallel ... | 2011-09-18 | due-trials |